Apr 14, 2014 atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. Pfizer is currently recruiting for the nct02697864 healthy cancer trial. National clusterrandomized trial of dutyhour flexibility in. Apixaban in patients with atrial fibrillation article pdf available in new england journal of medicine 3649. Apixaban in patients with atrial fibrillation nejm.
A phase iii study of apixaban in patients with atrial. The commence aortic trial outcomes clinical summary. Use of vibrio cholerae vaccine in an outbreak in guinea. In this randomized, doubleblind trial, we compared apixaban at a dose of 5 mg twice daily with warfarin target international normalized ratio, 2. Effectiveness and safety of oral anticoagulants among. The use of oral anticoagulation in patients with atrial fibrillation at moderate or high risk of stroke, estimated by established criteria, improves outcomes. The purpose of this document is to describe how a randomized clinical trial comparing the harms and benefits of proprotein convertase subtilisinkexin type 9 pcsk9. Apixaban to prevent venous thromboembolism in patients.
Antithrombotic therapy after acute coronary syndrome or. The trial s secondary outcome, a composite recurrent vte, mi, cva, or cv death, occurred less frequently with aspirin compared to placebo 5. The trial was terminated early given a treatment benefit with apixaban. However, to ensure that the benefits exceed the risks of bleeding, appropriate patient selection is essential. Although effective, oral anticoagulation with warfarin to prevent stroke in patients with atrial fibrillation has limitations. Efficacy and safety of apixaban compared with aspirin in. Apixaban in patients with atrial fibrillation n engl j med 364. The averroes trial is one of two phase 3 clinical trials exploring the efficacy and safety of apixaban for stroke prevention in patients with af. Many consider the rct to be the most important medical development of the twentieth century, as their results are used to dictate clinical practice. Cerebral amyloid angiopathy is common among elderly patients, and is associated with an increased risk of intracerebral bleeding, especially with the. Apixaban versus warfarin in patients with atrial fibrillation. Results a total of 434 046 patients were included in the 6 matched cohorts. This multicenter, doubleblind, randomized control trial was conducted at 522 centers in 36 countries to gauge the safety and effectiveness of apixaban as compared to aspirin in patients with atrial fibrillation. Apixaban for reduction in stroke and other thromboembolic.
Bms and pfizer announce publication of results of averroes. Averroes nct00496769 was a randomised, doubleblind, doubledummy study to assess the superiority of apixaban 5 mg bid vs aspirin acetyl salicylic acid, asa 824 mgday for the prevention of stroke in 5,600 patients with af and at least one additional risk factor for stroke, who had failed or were considered unsuitable for vitamin k antagonist vka treatment 1. Efficacy and safety of apixaban compared with aspirin in the. Aspirin is the original wonder drug, used in various forms for thousands of years for its analgesic, antipyretic, and antiinflammatory properties 11, and more recently, for its ability to inhibit platelet aggregation, reducing the risk for occlusive vascular events associated with. Averroes was a doubleblind trial including 5599 patients from 36 countries who were at increased risk for stroke because of the presence of at least 1 risk factor in addition to atrial. The ongoing aristotle trial is investigating apixaban compared with warfarin in 18,206 patients with af. Outcome results leader trial was a cardiovascular cv outcomes trial conducted as a postmarketing requirement to evaluate cv safety as per the 2008 fda guidance titled diabetes. The trial enrolled 5599 patients who were older than 50. Data from this trial are expected to be presented at a major medical meeting later this year. Averroes apixaban versus acetylsalicylic acid to prevent strokes, a randomized, doubleblind, multicenter, headtohead trial, included 5,599 patients with atrial fibrillation at risk for stroke who were expected or demonstrated to be unsuitable for therapy with a vitamin k antagonist such as warfarin. The price of that drug, as sechtem pointed out, has been a major hurdle. The randomized clinical trial rct is the ultimate paradigm of clinical research.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Sep 12, 20 the averroes trial randomized patients unsuitable for warfarin to apixiban or aspirin. Averroes apixaban versus asa to prevent stroke in af patients who have failed or are unsuitable for vitamin k antagonist treatment trial n 5,599 included 1,898 patients. In the aristotle apixaban for reduction in stroke and other. Andes1537, a proprietary antisense oligonucleotide designed by andes biotechnology, is the companys most advanced investigational drug candidate and the first to enter a human clinical study. The phase 3 averroes apixaban versus acetylsalicylic acid asa to prevent strokes trial, designed to show the superiority of apixaban over aspirin for the prevention of stroke or systemic embolism in highrisk atrial fibrillation patients unsuitable for treatment with a vitamin k antagonist warfarin, was terminated early following a recommendation from the data monitoring committee.
New averroes data demonstrate investigational apixaban. Atrial fibrillation is a common arrhythmia that increases the risk of stroke. We compared the baseline characteristics and effects of apixaban compared with aspirin on clinical outcomes by age. Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. Antithrombotic therapy after acute coronary syndrome or pci. Averroes clinical trial in averroes, eliquis apixaban demonstrated superior stroke systemic embolism prevention with a comparable rate of major bleeding vs. A phase iii study of apixaban in patients with atrial fibrillation averroes the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Use of vibrio cholerae vaccine in an outbreak n engl j med 370. Review trial description, criteria and location information here. Ultrafiltration in decompensated heart failure with. Aug 27, 2017 in the fourier trial, presented and published in march, treatment with the pcsk9 inhibitor evolocumab repatha, amgen reduced the risk of cardiovascular death, mi, stroke, hospitalization for unstable angina, or coronary revascularization by 15% when compared with placebo. The averroes trial randomized patients unsuitable for warfarin to apixiban or aspirin. Limitations of aspire included its slow enrollment and failure to reach the 3,000 patients required in the trial s power calculation. In addition, it is a twicedaily oral medication that does not require routine inr or other blood level monitoring, thereby being more convenient to use compared with warfarin.
In a 2 x 2 factorial design, patients with atrial fibrillation undergoing coronary revascularization were randomized in a 1. In the midst of coronavirus disease 2019 covid19, the world and the health care sector in particular face an extreme state of vuca, the u. Listing a study does not mean it has been evaluated by the u. The primary endpoint of composite death from vascular causes, mi or stroke was reduced by. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack. Fda investigational device exemption trial 689 patients underwent surgical avr with the carpentieredwards perimount magna ease aortic valve with resilia tissue model 1a mean age 67. The avert trial was a randomized, placebocontrolled, doubleblind clinical trial comparing apixaban 2. Percutaneous left atrial appendage closure for stroke. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with nejm group information and services. Although these trails are often put on a pedestal, it is. Patients were randomized to ticagrelor versus clopidogrel during acute coronary syndrome.
The current trial extends those findings, and demonstrates superiority for strokesystemic embolism with apixaban compared with warfarin, with a better bleeding profile. Ultrafiltration in decompensated heart failure n engl j med 367. The multicenter protect af trial was conducted in 707 patients with nonvalvular atrial fibrillation and chads 2 score. Antiinflammatory agent canakinumab modestly reduces. Apixaban was superior for the group as a whole but there was no statistically significant advantage over aspirin in the 6575 year age group or in those with a chads 2 score of 0 or 1. With an aging population, clinicians are more frequently encountering patients with atrial fibrillation who are also at risk of intracerebral hemorrhage due to cerebral amyloid angiopathy, the result of.
540 1428 25 841 881 1356 1124 210 1428 572 131 808 756 698 334 397 2 1396 291 861 936 43 1240 1023 372 1120 410 140 686 422 1451